1. Clinical Overview
A fixed-dose combination (FDC) medication used primarily for the treatment of moderate to severe symptoms of Benign Prostatic Hyperplasia (BPH). Tamsulosin is a selective alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow. Dutasteride is a dual 5-alpha reductase inhibitor (Type I and II) that reduces intraprostatic dihydrotestosterone (DHT), leading to a decrease in prostate volume. This combination provides both rapid symptomatic relief (from Tamsulosin) and long-term disease modification by reducing prostate size and risk of complications (from Dutasteride).
| Onset | Duration | Bioavailability |
|---|---|---|
| Tamsulosin: Symptomatic relief (improved urine flow) may begin within 4-8 hours after the first dose, with full effect typically seen after 1-2 weeks of continuous dosing. Dutasteride: Reduction in prostate size and serum DHT occurs within 1-2 weeks, but clinical improvement in symptoms and reduction in prostate volume may take 3-6 months. | Tamsulosin: Approximately 24 hours, supporting once-daily dosing. Dutasteride: Very long; due to its long half-life, effects persist for weeks after discontinuation. | Tamsulosin: ~100% (from the modified-release capsule). Dutasteride: ~60% when taken with a fatty meal (bioavailability increases significantly with food). |
2. Mechanism of Action
The combination works via two complementary mechanisms to relieve BPH symptoms and alter disease progression. Tamsulosin selectively blocks postsynaptic alpha-1A adrenoceptors, which are predominant in the prostate stroma, prostatic capsule, and bladder neck. This blockade inhibits noradrenaline-induced smooth muscle contraction, leading to relaxation, reduced dynamic obstruction, and improved urinary flow. Dutasteride inhibits both Type I and Type II isoforms of the enzyme 5-alpha reductase, which converts testosterone to the more potent androgen dihydrotestosterone (DHT). This inhibition drastically reduces intraprostatic and serum DHT levels, causing apoptosis of prostate epithelial cells, reduction in prostate gland volume, and thus a decrease in the static component of bladder outlet obstruction.
3. Indications & Uses
- Treatment of moderate to severe symptoms of Benign Prostatic Hyperplasia (BPH) in men with an enlarged prostate
- Reduction in the risk of acute urinary retention (AUR) and the need for BPH-related surgery in men with moderate to severe symptoms and an enlarged prostate (>30cc) or elevated PSA (>1.5 ng/mL)
4. Dosage & Administration
Adult Dosage: One capsule (Tamsulosin 0.4mg + Dutasteride 0.5mg) orally once daily, approximately 30 minutes after the same meal each day (preferably breakfast or dinner).
Administration: Swallow the capsule whole with a glass of water. Do not crush, chew, or open the capsule, as this can affect the modified-release properties of tamsulosin. Should be taken after a meal at the same time each day to ensure consistent absorption, particularly for dutasteride. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose.
5. Side Effects
Common side effects may include:
- Abnormal ejaculation/retrograde ejaculation (reduced semen volume)
- Decreased libido (sex drive)
- Erectile dysfunction (impotence)
- Dizziness
- Postural hypotension (dizziness upon standing)
- Headache
- Fatigue/asthenia
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Alpha-1 Blockers (e.g., Prazosin, Terazosin, Doxazosin, Alfuzosin) | Additive hypotensive effects, increased risk of orthostatic hypotension and syncope. | Major |
| Phosphodiesterase-5 Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) | Additive blood pressure-lowering effects, leading to symptomatic hypotension. | Major |
| Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Clarithromycin) | May increase plasma concentrations of both tamsulosin and dutasteride, increasing the risk of adverse effects, especially hypotension. | Moderate to Major |
| Antihypertensives (e.g., Beta-blockers, ACE Inhibitors, Calcium Channel Blockers, Diuretics) | Potential additive blood pressure-lowering effect, increasing risk of dizziness and hypotension. | Moderate |
| Cimetidine | May increase tamsulosin levels by reducing its metabolism. | Moderate |
| Warfarin | Dutasteride has been shown to have no clinically significant interaction, but monitoring is always prudent when adding new drugs. | Minor |
7. Patient Counselling
- DO take the capsule once daily, after the same meal (e.g., breakfast) to help you remember and ensure proper absorption.
- DO swallow the capsule whole with a glass of water. Do NOT crush, chew, or open it.
- DO inform all your doctors and surgeons (especially eye surgeons for cataract) that you are taking this medicine.
- DO get up slowly from a sitting or lying position, especially during the first few weeks, to avoid dizziness.
- DON'T take this medicine if you are a woman, especially if you are pregnant or planning pregnancy. Avoid handling broken capsules.
- DON'T drive or operate heavy machinery if you feel dizzy or fatigued.
- DON'T stop taking this medicine without consulting your doctor, even if you feel better. Symptoms may return.
8. Toxicology & Storage
Overdose: Primarily an extension of tamsulosin's alpha-blockade effects: Severe hypotension (dizziness, fainting), tachycardia, and possibly shock. Symptoms from dutasteride overdose are unlikely to be acute due to its long half-life but could include prolonged hormonal effects.
Storage: Store at room temperature (15-30°C), protected from light and moisture. Keep the container tightly closed. Keep out of reach of children and pets. Do not use after the expiry date printed on the pack. Dispose of unused medicine properly; do not flush.